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A B S T R A C T
Following greater attention and follow-up of patients with treated pulmonary tuberculosis (TB), it has
emerged that infections are more likely to occur in this cohort of patients. This comes as no surprise, as
pulmonary TB is a destructive process that leads to cicatrization, alteration of parenchyma,
bronchiectasis, and scarring of the lung, with reduction of lung volumes and an impact on pulmonary
function. In addition to relapse and re-infection with TB, other pathogens are increasingly recognized in
post-TB patients. This paper serves as a summary and guide on how to approach the post-TB patient with
new signs and symptoms of pulmonary infection in order to ensure optimal management and
rehabilitation.
© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction and approach
Patients with pulmonary tuberculosis (TB), even after cure, may
develop further respiratory infections and lung disease, which may
become chronic, leading to greater morbidity and mortality
(Hnizdo et al., 2000). Exacerbations of chronic obstructive
pulmonary disease (COPD), bronchiectasis, and pneumonia are
more frequent after pulmonary TB (Amaral et al., 2015; Byrne et al.,
2015). Lung aging is accelerated, especially in the presence of
smoking and atmospheric pollution (Glaser et al., 2015; van Zyl
Smit et al., 2010). Colonization and infection with non-tuberculous
mycobacteria (NTM) and Aspergillus fumigatus are common in
individuals with a degree of pre-existing lung destruction (Brode
et al., 2014; Pasqualotto and Denning, 2008). In addition to TB
recurrence or reinfection, all of these conditions need to be
considered in the differential diagnosis when patients present with
symptoms following the treatment of pulmonary TB and/or any
evidence of lung function deterioration or TB sequelae is noticed.
Post-TB infections may present with similar clinical features to
pulmonary TB, with haemoptysis being a common manifestation.
The authors recommend taking a chest X-ray at the end of TB
treatment, as this is useful for future comparison. The presence of
cavitary disease may prompt the clinician to consider baseline
Aspergillus serology. Vaccination for influenza virus may be useful
in reducing further infectious insults and inflammation (Oei and
Nishiura, 2012; Noymer, 2009). Six-monthly respiratory clinic
follow-up in the 2 years after TB treatment may be useful in the
monitoring and management of possible COPD and bronchiectasis
in a subset of patients with chronic lung disease, who might need
pulmonary rehabilitation. Clinicians should also be aware of the
possibility, and associated higher mortality, of NTM–Aspergillus co-
infection (Jhun et al., 2017; Naito et al., 2018).
Chronic pulmonary aspergillosis: clinical picture and
management
Chronic pulmonary aspergillosis (CPA) encompasses a spec-
trum of disease patterns, often with considerable overlap. The
major subtypes of CPA include chronic cavitary aspergillosis (CCA),
chronic fibrosing aspergillosis (CFA), aspergilloma, and Aspergillus
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nodules. A. fumigatus is the causative species, but Aspergillus niger
and Aspergillus flavus infections have also been reported (Pasqua-
lotto and Denning, 2008; Severo et al., 1997). It has been estimated
that patients with residual pulmonary cavities of 2 cm after TB
treatment have a 20% chance of developing aspergillomas (British
Thoracic and Tuberculosis Association, 1970). Overall estimates of
the mortality rate in CPA where treatment is available range from
20–33% in the short-term to 33–80% over a 5-year period (Camuset
et al., 2007; Jewkes et al., 1983; Lowes et al., 2017; Ohba et al.,
2012).
Clinical features of CPA are usually non-specific and indolent in
onset. Common symptoms include weight loss, chronic productive
cough, fatigue, dyspnoea, and haemoptysis (Schweer et al., 2014). A
simple aspergilloma without concurrent CCA/CFA often causes few
or no symptoms.
Chest imaging remains an important diagnostic modality. A
chest X-ray or computed tomography (CT) scan can reveal one or
more cavities, typically within the upper lobes, of variable size,
with or without the presence of pleural thickening and fibrosis
(Desai et al., 2015). Cavities can be thin- or thick-walled, and may
or may not contain fungal balls. A simple aspergilloma is usually
within a single cavity, with limited inflammation, pleural
thickening, and fibrosis (Denning et al., 2003).
The mainstay for diagnosis is the detection of Aspergillus-
specific IgG in serum (Denning et al., 2018; Denning et al., 2016;
Takazono and Izumikawa, 2018). ELISA-based commercial assays
are more sensitive and specific than conventional Aspergillus
precipitin testing (Page et al., 2017). Limitations include false-
negative results in patients who fail to mount an antibody
response, low sensitivity with non-fumigatus species, and false-
positive results with non-CPA aspergillosis (Takazono and Izumi-
kawa, 2018). Clinical and radiological correlation is therefore
paramount (Denning et al., 2018, 2016; Takazono and Izumikawa,
2018).
The sensitivity of galactomannan in bronchoalveolar lavage
(BAL) is far superior to that in serum (Sehgal et al., 2019; Shin et al.,
2014). PCR-based detection of Aspergillus species for CPA diagnosis
has been reported to be more sensitive than culture; however
false-positive results may occur (Fraczek et al., 2014; Vergidis et al.,
2019; Zhao et al., 2016).
Management depends on the extent and type of disease and
whether the patient is a candidate for surgical resection (Denning
et al., 2016). The risks and benefits of treatment must be
considered in each individual patient. Data on the optimal
duration and choice of antifungal agents are limited (Agarwal
et al., 2013; Kohno et al., 2010). Voriconazole, isavuconazole, or
itraconazole are first-line treatment options for individuals with
CCA or CFA (Denning et al., 2016; Maghrabi and Denning, 2017;
Patterson et al., 2016). Posaconazole is an alternative. Serum
therapeutic drug monitoring is essential to optimize dosing
initially (Ullman et al., 2018). Amphotericin B, micafungin, or
caspofungin are intravenous alternatives if there is failure,
intolerance, or resistance to the above treatment options (Denning
et al., 2016; Maghrabi and Denning, 2017). With some centres in
Western Europe reporting resistance rates of >25%, relative cross-
resistance to multiple azoles is an increasing concern (Bueid et al.,
2010; Fuhren et al., 2015).
A minimum treatment duration of 4–6 months is recom-
mended for patients with CCA (Denning et al., 2016). However,
individuals with progressive disease, poor response, or ongoing
immunosuppression may require a longer duration. Lifelong
therapy is required in a subset of patients with progressive
disease (Patterson et al., 2016). Radiographic variation in cavity/
pleural thickening and reduction/resolution of fungal ball can be
used for assessment of the treatment response (Godet et al.,
2016).
For individuals with a simple aspergilloma, surgical resection
can prevent or treat severe haemoptysis (Patterson et al., 2016).
Embolization can be done prior to surgery, or in patients for whom
surgery is not possible (Denning et al., 2016).
Bronchiectasis: clinical features, management, and
rehabilitation
Bronchiectasis may appear in the course of active TB or develop
as a sequela of TB. A systematic review of 27 studies that evaluated
patients after recovery from TB based on CT imaging reported
bronchiectasis in 35–86% of patients (Meghji et al., 2016).
Bronchial stenosis and scarring in post-TB patients or external
compression of bronchi by enlarged lymph nodes can lead to
retention of secretions and recurrent infection, further leading to
destruction and dilatation of the airways. Fibrosis and destruction
of the lung parenchyma can also cause bronchiectasis by
parenchymal retraction (Kim et al., 2001).
While bronchiectasis may be localized or diffuse, it most
frequently affects the apical and posterior segments of the
upper lobes (the most common sites of post primary TB) (Smith,
2017).
One of the major complications of bronchiectasis is frequent
exacerbations of disease due to recurrent infections, progressively
deteriorating lung function and reducing exercise tolerance and
quality of life (QoL) (Spruit, 2014; Spruit et al., 2013). This recurring
cycle of infection is due to the interplay between structural lung
damage, persistent inflammation, bacterial and fungal coloniza-
tion of the respiratory tract, and mucociliary insufficiency.
Frequent infectious exacerbations in bronchiectasis patients are
associated with higher rates of hospitalization and increased
mortality, as well as incremental costs for the health system (Finch
et al., 2015; Spruit, 2014; Spruit et al., 2013). Clinical manifestations
of disease include a productive cough – often associated with
haemoptysis. Pleuritic chest pain, dyspnoea, fever, fatigue, and
weight loss are common clinical features (Smith, 2017).
Microbiology of recurrent infections exclusively in post-TB non-
cystic fibrosis (CF) bronchiectatic patients is limited. However, data
can be extrapolated from studies on all non-CF bronchiectasis
patients, especially from settings with high TB endemicity.
Commonly associated microorganisms in infectious exacerbations
include Pseudomonas aeruginosa, Haemophilus influenzae, Morax-
ella catarrhalis, and Staphylococcus aureus (Dhar et al., 2019).
Burkholderia cepacia complex, Stenotrophomonas maltophilia, and
other members of the Pseudomonadaceae family are increasingly
recognized as causative organisms (Tunney et al., 2013; Kenna
et al., 2017). This change has been attributed to advances in
microbial diagnosis, enhanced sputum surveillance, and long-term
suppressive antibiotic treatment (Green and Jones, 2015). NTM are
also commonly isolated in bronchiectasis patients with infectious
exacerbations (Chandrasekaran et al., 2018).
Medical management includes pulmonary rehabilitation (air-
way clearance through chest physiotherapy, inhaled hypertonic
saline, and exercise if indicated) aimed at reducing the frequency
and severity of recurrent infections, improving exercise tolerance
and QoL (Spruit, 2014; Spruit et al., 2013).
Long-term antibiotics are given to prevent recurrent exacer-
bation and break this vicious cycle. Several trials have demon-
strated a significant reduction in exacerbation frequency using
long-term macrolide therapy (either 6 or 12 months) compared to
placebo (Altenburg et al., 2013; Serisier et al., 2013). However, this
practice may lead to selecting macrolide-resistant microorgan-
isms including NTM. Inhaled antibiotics are also used to reduce
the bacterial burden and typically have fewer side effects
compared to oral antibiotics. However, tolerability and availabili-
ty can be an issue with inhaled antibiotics. Occasionally surgical
S42 D. Hsu et al. / International Journal of Infectious Diseases 92S (2020) S41–S45
resection of the involved segment or lobe may be indicated when
there is failure of medical management of localized disease
(Watanabe et al., 2006).
Non-tuberculous mycobacterial infection
Evidence suggests that the global burden of NTM infection is
increasing (Brode et al., 2014). The most frequently isolated NTM
from pulmonary samples is Mycobacterium avium–intracellulare
complex (MAC) (Shah et al., 2016). Mycobacterium kansasii is
another important cause of progressive pulmonary disease.
Patients with pre-existing structural lung disease – including
bronchiectasis and prior TB – are at risk of developing NTM lung
disease (Fowler et al., 2006). NTM co-isolation occurs in 7–11% of
patients with pulmonary TB (Damaraju et al., 2013; Hsing et al.,
2013).
Clinical features of MAC lung disease are variable and non-
specific and include cough, fatigue, dyspnoea, chest discomfort,
haemoptysis, weight loss, and fever. M. kansasii presents more
acutely. Radiological findings for both include parenchymal
infiltration, nodules, and cavitation (Christensen et al., 1978;
Swensen et al., 1994). Diagnostic criteria include compatible
clinical/radiological features with either one or two positive
microbiological results from bronchial lavage or sputum samples,
respectively, or with suggestive histopathological features on
biopsy (Griffith et al., 2007). The advent of accessible whole
genome sequencing may change the diagnostic context for
differentiation between infection and colonization.
The decision to start treatment for patients who meet
diagnostic criteria is influenced by the severity of disease, the
risk of progression, the presence of comorbidities, the tolerability
of treatment, and the goals of treatment. The presence of
fibrocavitary disease is associated with more rapid progression
and calls for rapid start of treatment (Griffith et al., 2007). The
treatment regimen depends on susceptibility to macrolides. Most
guidelines suggest a three-drug regimen comprising rifampicin,
ethambutol, and azithromycin or clarithromycin (Griffith et al.,
2007; Haworth et al., 2017). Antibiotics can be administered three
times a week for individuals with mild to moderate severity and
with no evidence of fibrocavitary disease. Patients with severe
disease or fibrocavitary disease require daily dosing of rifampicin,
ethambutol, and azithromycin or clarithromycin, with consider-
ation of a fourth agent in the form of either intravenous or
nebulized amikacin (Haworth et al., 2017). The treatment duration
is a minimum of 12 months after sputum culture conversion
(Haworth et al., 2017). Therapeutic drug monitoring should be
performed routinely for aminoglycosides, and should be consid-
ered for other drugs in individuals where there is a concern about
malabsorption, drug–drug interactions, or suboptimal adherence
(Haworth et al., 2017). There remains an urgent need for research
into novel drugs or new combinations of existing drugs for NTM
infections.
Prevention and vaccination
Mathematical modelling of epidemiological data suggests that
there is an increase in frequency and severity of influenza-
associated disease during pandemics and seasonal epidemics in
individuals with pulmonary TB compared to healthy individuals
(Oei and Nishiura, 2012; Noymer, 2009; Zürcher et al., 2016).
Influenza and TB co-infection can impair host immune responses
leading to increased susceptibility to secondary bacterial infec-
tions (Ballinger and Standiford, 2010; Small et al., 2010). The
resultant increased risk of severe outcomes can potentially be
mitigated by timely empirical antiviral therapy in individuals with
possible influenza infection. Seasonal influenza vaccination is
recommended for patients with chronic pulmonary conditions in
most international guidelines (Public Health England, 2019;
European Centre for Disease Prevention and Control, 2008). As
the severity and chronicity of lung disease differs between
individuals with treated pulmonary TB, influenza vaccination
should be considered particularly for those with established
chronic respiratory disease.
Cigarette smoking is a risk factor for pulmonary infections, as
well as a co-factor contributing to rapid lung function deteriora-
tion, reduced exercise tolerance, and impaired QoL (Muñoz-Torrico
et al., 2016; Spruit, 2014; Spruit et al., 2013). A number of studies
have demonstrated a reduction in frequency and severity of
exacerbations in individuals with established chronic lung disease
(Willemse et al., 2004; Au et al., 2009). Additionally, population-
based studies have demonstrated correlations between smoking
and the development of adverse outcomes, relapse, and develop-
ment of drug-resistant TB (Zhang et al., 2016). A comprehensive
smoking cessation and pulmonary rehabilitation programme
(Chalmers et al., 2015) is likely to be an important strategy in
reducing infective exacerbations in patients with established lung
disease.
Conclusions and summary
Awareness of post-TB lung health is increasingly important
and gaining more attention. It is increasingly recognized that
patients completing TB treatment should be followed up in time,
especially if there are significant lung changes or cavities. Patients
with evidence of COPD/bronchiectasis are particularly likely to
experience further infectious insults and decline in lung function,
with hampering of quality of life. The authors consider end of
treatment spirometry, sputum for acid-fast bacilli, screening for
Aspergillus, and a chest X-ray to be helpful when assessing a post-
TB patient presenting subsequently with potential relapse of TB,
non-specific infection, neoplasia, or other sequelae. Smoking
cessation, vaccination, preventive antibiotics, and pulmonary
rehabilitation may help curb exacerbations, reduce lung function
decline, and improve quality of life.
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